Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

Program Description

This clinical panel debate to follow the follicular lymphoma session during PTCE's 2025 Lymphoma Day of Education will challenge pharmacists to apply their knowledge to real-world patient case scenarios, comparing chimeric antigen receptor (CAR) T-cell therapy with bispecific antibodies and delving into critical decision-making points such as patient eligibility, logistical considerations, and comprehensive adverse effect management.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: September 30, 2025
Expiration date: September 30, 2026
Learner level: Advanced
Time to complete activity: 0.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Examine the clinical and logistical factors that influence the selection of chimeric antigen receptor (CAR) T-cell therapy versus bispecific antibodies (BsAbs) for patients with relapsed/refractory follicular lymphoma (R/R FL)
2. Analyze patient- and treatment-specific criteria to determine the most appropriate use of CAR T-cell therapy or BsAbs in R/R FL 
3. Determine approaches for the safe integration of BsAbs and CAR T in R/R FL including outpatient monitoring